金刚烷杂质18 | 81968-77-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 金刚烷杂质18
• 英文名称: 4a-hydroxy-1-adamantanecarboxylic acid
• 英文别名: 4e-hydroxy-1-adamantanecarboxylic acid；4-hydroxyadamantane-1-carboxylic Acid
• CAS: 81968-77-6
• 化学式: C₁₁H₁₆O₃
• 分子量: 196.246
• InChiKey: DFNDMKWFBDOGMU-UHFFFAOYSA-N

物化性质

• 熔点：
  117-128 °C(mixture of isomers)
• 沸点：
  366.9±35.0 °C(Predicted)
• 密度：
  1.368±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  金刚烷杂质18 在 吡啶 、 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 1-乙酰基-4-金刚烷醇肟
  参考文献：
  名称：

  Synthesis and antiviral activity of metabolites of rimantadine

  摘要：

  The hydroxy metabolites of rimantadine (3-5) were synthesized and compared to amantadine (1) and rimantadine (2) for their ability to inhibit the replication of influenza viruses in vitro. All three metabolites were inhibitory to wild-type influenza A viruses (H3N2 and H1N1). In particular, 2-hydroxyrimantadine (3) showed similar activity to amantadine, but the 3- and 4-hydroxy metabolites (4 and 5, respectively), both of which are found in rimantadine-treated patients, showed only modest inhibitory activity. A rimantadine-resistant isolate of influenza A virus exhibited cross-resistance to amantadine and to each of the metabolites 3-5. None of the compounds were effective against influenza B virus.

  DOI：

  10.1021/jm00169a029
• 作为产物：
  描述：

  2-金刚烷酮-5-甲酸 在 甲醇 、 sodium tetrahydroborate 作用下， 以60 %的产率得到金刚烷杂质18
  参考文献：
  名称：

  使用便宜且容易获得的四氟硼酸盐进行氟化

  摘要：

  已经开发出一种实用的电化学方法，用于从羧酸快速、安全和温和地合成叔受阻烷基氟化物，而无需氢氟酸盐或非玻璃反应器。在这种阳极氟化反应中，四氟硼酸可力丁作为支持电解质和氟化物供体。广泛的官能团已被证明是相容的，并且还证明了使用流式电化学进行放大的可能性。

  DOI：

  10.1021/acs.orglett.2c04305

文献信息

• INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Claremon David A.

  公开号：US20110034455A1

  公开（公告）日：2011-02-10

  This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  这项发明涉及到式(I*)的新化合物，其药用盐以及药物组合物，这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。
• [EN] CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1<br/>[FR] INHIBITEURS DE LA 11BÊTA-HYDROXYSTÉROÏDE-DÉSHYDROGÉNASE 1 À BASE DE CARBAMATES ET D'URÉE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2010141424A1

  公开（公告）日：2010-12-09

  This invention relates to novel compounds of the invention pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  这项发明涉及本发明的新化合物及其药用盐，以及其药物组合物，这些化合物对于治疗与哺乳动物中的11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。
• [EN] FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF<br/>[FR] COMPOSÉS À CYCLES CONDENSÉS, COMPOSITION PHARMACEUTIQUE ET UTILISATIONS ASSOCIÉES
  申请人：SHANGHAI DE NOVO PHARMATECH CO LTD

  公开号：WO2016131380A1

  公开（公告）日：2016-08-25

  This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.

  这份披露涉及到式(I)的融合环化合物和/或其药学上可接受的盐，包括式(I)的融合环化合物和/或其药学上可接受的盐的药物组合物，其制备方法，以及在调节吲哚胺2,3-二氧化酶(IDO)和/或色氨酸2,3-二氧化酶(TDO)活性中的应用。这份披露还提供了治疗IDO和/或TDO相关疾病的方法，包括癌症、病毒感染和自身免疫疾病。
• Indazolecarboxamides
  申请人：Eli Lilly and Company

  公开号：US05654320A1

  公开（公告）日：1997-08-05

  Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.

  Indazolecarboxamides被用作5-HT.sub.4受体的拮抗剂和部分激动剂，并提供治疗由5-HT.sub.4受体功能失调引起或受其影响的疾病的治疗方法。
• SALT AND PHOTORESIST COMPOSITION CONTAINING THE SAME
  申请人：Sumitomo Chemical Company, Limited

  公开号：US20190107778A1

  公开（公告）日：2019-04-11

  A salt represented by the formula (I):

  由化学式(I)表示的盐：